MedTrace Logo

Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics

NCT00656604 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-03-05

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI), magnetic resonance spectroscopy (MRS), and tissue proteomics, may help doctors find and diagnose breast cancer and plan the best treatment.

PURPOSE: This clinical trial is studying MRI and MRS with or without tissue proteomics analysis to see how well they work in evaluating healthy women and women who are undergoing surgery for breast cancer.

Conditions

Interventions

GENETIC

proteomic profiling

at the time of each procedure.

PROCEDURE

lumpectomy or mastectomy

removal of breast tumor or removal of the entire breast in which the tumor is located

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Prior to initiation of treatment

PROCEDURE

histopathologic examination

After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer

PROCEDURE

magnetic resonance spectroscopy

Prior to initiation of treatment

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • A. Bapsi Chakravarthy, MD · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2005-10-31
Completion
2008-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00656604 on ClinicalTrials.gov